Hydrochloric Acid

Hydrochloric Acid

SCHEMBL193696

O=P(O)(O)CC[n+]1ccc(-c2cc[n+](-c3cccc4ccccc34)cc2)cc1.[Cl-].[Cl-]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACP3 P15309 6/20 0.40
▸ CA12 O43570 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ MMP2 P08253 1/20 0.35
▸ MMP9 P14780 1/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ MMP14 P50281 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ FDPS P14324 1/20 0.35
▸ PLK1 P53350 1/20 0.34
▸ CHAT P28329 1/20 0.33
▸ PTK2B Q14289 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030925 0.99 ACP3 (0.41) ACP3CA12CA2MMP2MMP9
Hydrochloric Acid SCHEMBL6442994 0.81 MEN1 (0.32) ALDH1A1
Hydrochloric Acid SCHEMBL600629 0.80 ACP3 (0.38) ACP3MMP2MMP9ALDH1A1
Hydrochloric Acid SCHEMBL2464559 0.80 ALDH1A1 (0.39) CHATALDH1A1
Hydrochloric Acid SCHEMBL602419 0.79 SLC22A12 (0.32) —
Hydrochloric Acid SCHEMBL2258374 0.79 ACP3 (0.39) ACP3CA2PTK2BL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL2259611 0.78 ACP3 (0.40) ACP3CA12CA2MMP2MMP9
SCHEMBL12715301 0.78 ALDH1A1 (0.40) ALDH1A1
Hydrochloric Acid SCHEMBL210855 0.78 MEN1 (0.38) ACP3ALDH1A1SMN1; SMN2
SCHEMBL6030921 0.76 ACP3 (0.40) ACP3CA12CA2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8786932-B2 Advanced electrode structures and electrochromic devices NTERA, INC. (US) 2014-07-22 — — US claimed
US-20120038967-A1 ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES NTERA LIMITED (IE) 2012-02-16 — — US claimed
EP-2401650-A1 ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES Ntera, Inc. (US) 2012-01-04 — — EP claimed
WO-2010099147-A1 ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES NTERA INC. (US) 2010-09-02 — — WO claimed
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2009-10-15 — — US claimed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US claimed
EP-1594938-A1 ELECTROCHROMIC COMPOUNDS Ntera Limited (IE) 2005-11-16 — — EP claimed
WO-2004067673-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2004-08-12 — — WO claimed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP claimed
US-8999430-B2 Method of manufacturing display element KONICA MINOLTA HOLDINGS, INC. (JP) 2015-04-07 — — US disclosed
US-8786932-B2 Advanced electrode structures and electrochromic devices NTERA, INC. (US) 2014-07-22 — — US disclosed
EP-2149816-B1 METHOD OF MANUFACTURING AN ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS INC (JP) 2014-05-07 — — EP disclosed
US-20120038967-A1 ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES NTERA LIMITED (IE) 2012-02-16 — — US disclosed
EP-2401650-A1 ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES Ntera, Inc. (US) 2012-01-04 — — EP disclosed
US-7567371-B2 Electrochromic compounds NTERA LIMITED (IE) 2009-07-28 — — US disclosed
EP-2040115-A1 ELECTROCHROMIC DISPLAY DEVICE Konica Minolta Holdings, Inc. (JP) 2009-03-25 — — EP disclosed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US disclosed
EP-1594938-A1 ELECTROCHROMIC COMPOUNDS Ntera Limited (IE) 2005-11-16 — — EP disclosed
WO-2004067673-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2004-08-12 — — WO disclosed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS ETV6, HCN2, EED ACP3 2868/4885CA12 405/4885CA2 2022/4885
US-20060110638-A1 Electrochromic compounds ETV6, HCN2, EED ACP3 2868/4885CA12 405/4885CA2 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback